StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)

Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –

Biogen operating margin

Operating margin is operating income as a percentage of revenue.

Biogen's operating margin for the twelve months ending Mar 31, 2022 was 22.9%. For fiscal 2021 it was 25.9%, against 33.8% the year before. The highest annual figure on record is 49.0% in fiscal 2019.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2021Dec 31, 202125.9%−8.0
FY2020Dec 31, 202033.8%−15.1
FY2019Dec 31, 201949.0%+5.2
FY2018Dec 31, 201843.8%+0.2
FY2017Dec 31, 201743.6%−1.4
FY2016Dec 31, 201645.0%−0.4
FY2015Dec 31, 201545.4%+4.5
FY2014Dec 31, 201440.9%+4.7
FY2013Dec 31, 201336.3%+2.6
FY2012Dec 31, 201233.6%−0.5
FY2011Dec 31, 201134.2%+7.7
FY2010Dec 31, 201026.5%−3.1
FY2009Dec 31, 200929.6%−0.0
FY2008Dec 31, 200829.6%+5.0
FY2007Dec 31, 200724.6%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2022Mar 31, 202224.1%−12.0
Q4 FY2021Dec 31, 202121.5%+33.1
Q3 FY2021Sep 30, 202128.6%−3.6
Q2 FY2021Jun 30, 202117.5%−36.1
Q1 FY2021Mar 31, 202136.2%−15.3
Q4 FY2020Dec 31, 2020-11.6%−60.0
Q3 FY2020Sep 30, 202032.2%−18.0
Q2 FY2020Jun 30, 202053.6%−0.4
Q1 FY2020Mar 31, 202051.5%+8.4
Q4 FY2019Dec 31, 201948.4%+7.5
Q3 FY2019Sep 30, 201950.2%+0.8
Q2 FY2019Jun 30, 201954.1%+17.9
Q1 FY2019Mar 31, 201943.1%−6.0
Q4 FY2018Dec 31, 201840.9%−3.4
Q3 FY2018Sep 30, 201849.4%−4.4
Q2 FY2018Jun 30, 201836.1%−2.9
Q1 FY2018Mar 31, 201849.0%+12.6
Q4 FY2017Dec 31, 201744.3%+13.4
Q3 FY2017Sep 30, 201753.7%–
Q2 FY2017Jun 30, 201739.0%–
Q1 FY2017Mar 31, 201736.5%–
Q4 FY2016Dec 31, 201630.9%–

More Biogen figures

See a number that looks wrong?